To evaluate the therapeutic impact of (18)F-fluorocholine (FCH) PET/CT in biochemical recurrent prostate cancer (PC) and to investigate the value of quantitative FCH PET/CT parameters in predicting progression-free survival (PFS).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This retrospective study included 172 consecutive patients with PC who underwent FCH PET/CT for biochemical recurrence Mean rising PSA was 10 7 ± 35 0 ng/ml Patients with positive FCH PET were classified into three groups: those with uptake only in the prostatic bed, those with locoregional disease, and those with distant metastases Referring physicians were asked to indicate the hypothetical therapeutic strategy with and without the FCH PET/CT results Clinical variables and PET parameters including SUVmax, SUVpeak, SUVmean, total lesion choline kinase activity (TLCKA) and standardized added metabolic activity (SAM) were recorded and a multivariate analysis was performed to determine the factors independently predicting PFS
In 137 of the 172 patients, the FCH PET/CT scan was positive, and of these, 29 9 % (41/137) had prostatic recurrence, 42 3 % (58/137) had pelvic lymph node recurrence with or without prostatic recurrence, and 27 7 % (38/137) had distant metastases The FCH PET/CT result led to a change in treatment plan in 43 6 % (75/172) of the 172 patients Treatment was changed in 49 6 % (68/137) of those with a positive FCH PET/CT scan and in 20 % (7/35) of those with a negative FCH PET/CT scan After a median follow-up of 29 3 months (95 % CI 18 9 - 45 9 months), according to multivariate analysis age
This study indicates that a positive FCH PET result in PC patients with biochemical recurrence predicts a shorter PFS and confirms the major impact of the FCH PET result on the management of biochemical recurrent PC
European journal of nuclear medicine and molecular imaging 2015 Jul 21 [Epub ahead of print]
M Colombié, L Campion, C Bailly, D Rusu, T Rousseau, C Mathieu, L Ferrer, N Rousseau, F Kraeber-Bodéré, C Rousseau
Nuclear Medicine, Institut de Cancérologie de l'Ouest René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-St Herblain Cedex, France